<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>29(8)</volume><submitter>Verstovsek S</submitter><funding>National Cancer Institute of Health</funding><funding>MD Anderson Cancer Center</funding><journal>Annals of oncology : official journal of the European Society for Medical Oncology</journal><pagination>1880-1882</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6887683</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor.</pubmed_title><pmcid>PMC6887683</pmcid><funding_grant_id>CA016672</funding_grant_id><pubmed_authors>Masarova L</pubmed_authors><pubmed_authors>Asatiani E</pubmed_authors><pubmed_authors>Manshouri T</pubmed_authors><pubmed_authors>Verstovsek S</pubmed_authors><pubmed_authors>Subbiah V</pubmed_authors><pubmed_authors>Daver NG</pubmed_authors><pubmed_authors>Yin CC</pubmed_authors><pubmed_authors>Tang G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor.</name><description/><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Aug</publication><modification>2025-04-04T10:38:41.342Z</modification><creation>2025-04-04T10:38:41.342Z</creation></dates><accession>S-EPMC6887683</accession><cross_references><pubmed>29767670</pubmed><doi>10.1093/annonc/mdy173</doi></cross_references></HashMap>